Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
2.050
-0.410 (-16.67%)
Jan 21, 2025, 4:00 PM EST - Market closed
Marker Therapeutics Employees
Marker Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 59 or -88.06% compared to the previous year.
Employees
8
Change (1Y)
-59
Growth (1Y)
-88.06%
Revenue / Employee
$674,481
Profits / Employee
-$1,212,095
Market Cap
18.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
MRKR News
- 4 weeks ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 4 weeks ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire
- 6 weeks ago - Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - GlobeNewsWire
- 2 months ago - Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewsWire
- 2 months ago - Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma - GlobeNewsWire